Click here to view online. Add this email to your safelist.
Fasenra receives approval in Japan
19 January 2018
AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the Japanese Ministry of Health, Labour and Welfare has approved Fasenra (benralizumab) as an add-on treatment for bronchial asthma in patients who continue to experience asthma exacerbations despite treatment with high-dose inhaled corticosteroid and other asthma controllers.
|
|||||
|
|||||
|
For more information please visit astrazeneca.com. If you would like to unsubscribe please click here. |
